

Anna M Czarnecka

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3404548/anna-m-czarnecka-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

2,389
citations

25
h-index

40
g-index

189
ext. papers

3,033
ext. citations

3.8
avg, IF

5.27
L-index

#	Paper	IF	Citations
160	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016 , 15, 83	42.1	129
159	Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. <i>Cancer Biology and Therapy</i> , 2006 , 5, 714-20	4.6	116
158	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020 , 12,	6.6	94
157	Three-dimensional cell culture model utilization in cancer stem cell research. <i>Biological Reviews</i> , 2017 , 92, 1505-1520	13.5	72
156	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 511-8	4.4	62
155	Mitochondrial DNA mutations in human neoplasia. <i>Journal of Applied Genetics</i> , 2006 , 47, 67-78	2.5	62
154	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 283-96	5.6	60
153	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. <i>Stem Cell Reviews and Reports</i> , 2015 , 11, 919-43	6.4	59
152	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014 , 8, 218-228	0.8	56
151	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 31-41	11.2	54
150	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 178	8.3	52
149	Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. <i>European Journal of Histochemistry</i> , 2008 , 52, 221-8	2.1	47
148	Heat shock protein 10 and signal transduction: a "capsula eburnea" of carcinogenesis?. <i>Cell Stress and Chaperones</i> , 2006 , 11, 287-94	4	46
147	Insulin and IGFs in renal cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2015 , 22, R253-64	5.7	42
146	Interleukin-6 as an emerging regulator of renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 476-85	2.8	38
145	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	35
144	Balance between transcription and RNA degradation is vital for <i>Saccharomyces cerevisiae</i> mitochondria: reduced transcription rescues the phenotype of deficient RNA degradation. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1184-93	3.5	34

143	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
142	Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). <i>International Journal of Oncology</i> , 2014 , 44, 349-63	4.4	30
141	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016 , 16, 453	4.8	30
140	Hsp60 and Hsp10 as antitumor molecular agents. <i>Cancer Biology and Therapy</i> , 2007 , 6, 487-9	4.6	29
139	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. <i>Current Pharmaceutical Design</i> , 2016 , 22, 1756-66	3.3	29
138	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2014 , 10, 1095-111	3.6	27
137	Involvement of the CB cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. <i>BMC Cancer</i> , 2018 , 18, 583	4.8	26
136	Renin angiotensin system deregulation as renal cancer risk factor. <i>Oncology Letters</i> , 2017 , 14, 5059-5068	2.6	26
135	The role of the mitochondrial genome in ageing and carcinogenesis. <i>Journal of Aging Research</i> , 2011 , 2011, 136435	2.3	25
134	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. <i>Wspolczesna Onkologia</i> , 2018 , 22, 48-55	1	24
133	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. <i>PLoS ONE</i> , 2016 , 11, e0165718	3.7	23
132	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. <i>Future Oncology</i> , 2015 , 11, 2267-82	3.6	22
131	Hsp60 and human aging: Les liaisons dangereuses. <i>Frontiers in Bioscience - Landmark</i> , 2013 , 18, 626-37	2.8	22
130	Common mitochondrial polymorphisms as risk factor for endometrial cancer. <i>International Archive of Medicine</i> , 2009 , 2, 33		22
129	CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. <i>Histopathology</i> , 2008 , 52, 203-12	7.3	22
128	Hormone signaling pathways as treatment targets in renal cell cancer (Review). <i>International Journal of Oncology</i> , 2016 , 48, 2221-35	4.4	21
127	Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. <i>Pharmacological Reports</i> , 2017 , 69, 985-994	3.9	21
126	Mitochondrial DNA mutations in cancer--from bench to bedside. <i>Frontiers in Bioscience - Landmark</i> , 2010 , 15, 437-60	2.8	21

125	Rhabdomyosarcoma of the head and neck in children. <i>Wspolczesna Onkologia</i> , 2015 , 19, 98-107	1	20
124	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. <i>International Journal of Molecular Medicine</i> , 2016 , 38, 1887-1894	4.4	20
123	Choosing The Right Animal Model for Renal Cancer Research. <i>Translational Oncology</i> , 2020 , 13, 100745	4.9	19
122	Hsp10: anatomic distribution, functions, and involvement in human disease. <i>Frontiers in Bioscience - Elite</i> , 2013 , 5, 768-78	1.6	19
121	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. <i>Cell and Bioscience</i> , 2017 , 7, 71	9.8	18
120	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 210-218	0.8	18
119	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014 , 4, 194	5.3	18
118	Persistent Overexposure to N-Methyl-D-Aspartate (NMDA) Calcium-Dependently Downregulates Glutamine Synthetase, Aquaporin 4, and Kir4.1 Channel in Mouse Cortical Astrocytes. <i>Neurotoxicity Research</i> , 2019 , 35, 271-280	4.3	18
117	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F424-36	4.3	17
116	Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. <i>Behavioural Brain Research</i> , 2014 , 261, 79-88	3.4	17
115	Molecular oncology focus - is carcinogenesis a Mitochondriopathy?. <i>Journal of Biomedical Science</i> , 2010 , 17, 31	13.3	17
114	Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with L-DOPA and the nitric oxide donor, molsidomine. <i>Brain Research</i> , 2013 , 1541, 92-105	3.7	16
113	Metastasis-Initiating Cells in Renal Cancer. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 240-246	0.8	16
112	Mitochondrial genotype and breast cancer predisposition. <i>Oncology Reports</i> , 2010 , 24, 1521-34	3.5	16
111	Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. <i>Oncology Reports</i> , 2010 , 23, 531-5	3.5	16
110	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. <i>Journal of Cell Communication and Signaling</i> , 2019 , 13, 381-394	5.2	15
109	Functional significance of CD105-positive cells in papillary renal cell carcinoma. <i>BMC Cancer</i> , 2017 , 17, 21	4.8	15
108	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017 , 13, 31-49	3.6	15

107	Ovarian cancer as a genetic disease. <i>Frontiers in Bioscience - Landmark</i> , 2013 , 18, 543-63	2.8	14
106	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. <i>Future Oncology</i> , 2014 , 10, 2177-87	3.6	14
105	Breast cancer as a mitochondrial disorder (Review). <i>Oncology Reports</i> , 2009 , 21, 845-51	3.5	14
104	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
103	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. <i>Future Oncology</i> , 2015 , 11, 17-26	3.6	13
102	Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?. <i>Neurochemical Research</i> , 2017 , 42, 750-761	4.6	13
101	Aggressive osteoblastoma of the sphenoid bone. <i>Oncology Letters</i> , 2010 , 1, 367-371	2.6	13
100	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019 , 71, 149-163	2.2	13
99	Future perspectives for mTOR inhibitors in renal cell cancer treatment. <i>Future Oncology</i> , 2015 , 11, 801-13	3.6	12
98	Obstructive sleep apnea and cancer: effects of intermittent hypoxia?. <i>Future Oncology</i> , 2015 , 11, 3285-98	3.6	12
97	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019 , 16, 655-673	5.5	12
96	Biology of renal tumour cancer stem cells applied in medicine. <i>Wspolczesna Onkologia</i> , 2015 , 19, A44-51	1	12
95	Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians. <i>BMC Cancer</i> , 2011 , 11, 166	4.8	11
94	(99m)TC-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas. <i>Head and Neck</i> , 2011 , 33, 1739-46	4.2	11
93	Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. <i>Journal of Biomedical Science</i> , 2010 , 17, 73	13.3	11
92	Epithelioid Sarcoma-From Genetics to Clinical Practice. <i>Cancers</i> , 2020 , 12,	6.6	11
91	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. <i>Oncology Letters</i> , 2016 , 12, 3555-3562	2.6	11
90	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. <i>Cytotechnology</i> , 2017 , 69, 565-578	2.2	10

89	Triiodothyronine regulates cell growth and survival in renal cell cancer. <i>International Journal of Oncology</i> , 2016 , 49, 1666-78	4.4	9
88	Three-Dimensional Cell Culture Model Utilization in Renal Carcinoma Cancer Stem Cell Research. <i>Methods in Molecular Biology</i> , 2018 , 1817, 47-66	1.4	9
87	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. <i>Neuroscience</i> , 2017 , 340, 308-318	3.9	9
86	Decreased behavioral response to intranigally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. <i>Behavioural Brain Research</i> , 2015 , 283, 203-14	3.4	9
85	Renal cell carcinoma with intramyocardial metastases. <i>BMC Urology</i> , 2014 , 14, 73	2.2	9
84	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. <i>Oncology Reports</i> , 2016 , 35, 1433-43	3.5	9
83	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019 , 14, 729-742	5	9
82	Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo. <i>Scientific Reports</i> , 2020 , 10, 5379	4.9	8
81	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. <i>Oncology Letters</i> , 2016 , 11, 1101-1104	2.6	8
80	Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure. <i>Neurotoxicity Research</i> , 2017 , 31, 99-108	4.3	8
79	Diagnosis and treatment of malignant PEComa tumours 2020 , 16, 22-33		8
78	Chondrosarcoma-from Molecular Pathology to Novel Therapies. <i>Cancers</i> , 2021 , 13,	6.6	8
77	Molecular basis of carcinogenesis in diabetic patients (review). <i>International Journal of Oncology</i> , 2015 , 46, 1435-43	4.4	7
76	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. <i>Future Oncology</i> , 2014 , 10, 2493-508	3.6	7
75	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. <i>Oncology Letters</i> , 2014 , 8, 1312-1316	2.6	7
74	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	7
73	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020 , 30, 465-471	3.3	7
72	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020 , 65, 316-323	2.8	6

71	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 520-525	3.6	6
70	The use of sunitinib in renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 983-99	3.5	6
69	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11574-11574	2.2	6
68	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 203-209	0.8	6
67	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
66	Thyroid Hormones as Renal Cell Cancer Regulators. <i>Journal of Signal Transduction</i> , 2016 , 2016, 1362407		6
65	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018 , 28, 435-441	3.3	6
64	OC-0069 5x5 Gy with chemotherapy in borderline resectable soft tissue sarcomas: early results of a trial. <i>Radiotherapy and Oncology</i> , 2019 , 133, S31-S32	5.3	5
63	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019 , 42, 1878-1892	3.5	5
62	Serum EPO and VEGF levels in patients with sleep-disordered breathing and acute myocardial infarction. <i>Sleep and Breathing</i> , 2013 , 17, 1063-9	3.1	5
61	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017 , 8, 329	5.6	5
60	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. <i>Cancers</i> , 2020 , 12,	6.6	5
59	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
58	TP53 in Biology and Treatment of Osteosarcoma. <i>Cancers</i> , 2021 , 13,	6.6	5
57	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 151-162	5.4	4
56	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. <i>Future Oncology</i> , 2017 , 13, 593-602	3.6	4
55	Impaired glucose metabolism treatment and carcinogenesis. <i>Oncology Letters</i> , 2015 , 10, 589-594	2.6	4
54	Vulvar cancer as a target for molecular medicine. <i>Frontiers in Bioscience - Scholar</i> , 2011 , 3, 136-44	2.4	4

53	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020 , 11, 2404-2413	3.3	4
52	Snoring but not BMI influences aggressive behavior and concentration problems in children. <i>Otolaryngologia Polska</i> , 2015 , 69, 22-9	0.7	4
51	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
50	Feasibility and Long-Term Efficacy of PEComa Treatment-20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
49	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 409-421	4.1	4
48	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019 , 9, 7754	4.9	3
47	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. <i>Cytotechnology</i> , 2018 , 70, 761-782	2.2	3
46	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2018 , 14, 385-397	6.4	3
45	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. <i>International Journal of Oncology</i> , 2018 , 52, 768-786	4.4	3
44	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
43	Molecular biology of sarcoma 2019 , 14, 307-330		3
42	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021 , 13, 297-307	3.8	3
41	Chemotherapy of pancreatic solid pseudopapillary carcinoma [A case report and a literature review. <i>Cancer Treatment Communications</i> , 2016 , 7, 47-51		3
40	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 1053-1063	4	3
39	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. <i>Cancers</i> , 2020 , 12,	6.6	2
38	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018 , 35, 91	3.7	2
37	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. <i>Oncology Letters</i> , 2019 , 18, 3373-3380	2.6	2
36	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. <i>Pharmacological Reports</i> , 2017 , 69, 29-35	3.9	2

35	Nasopharyngeal chordoma in a patient with a severe form of sleep-disordered breathing: A case report. <i>Oncology Letters</i> , 2015 , 10, 1805-1809	2.6	2
34	Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study.. <i>Cancers</i> , 2022 , 14,	6.6	2
33	Malignant peripheral nerve sheath tumour (MPNST) 2019 , 14, 364-376		2
32	Mucosal melanoma Clinical presentation and treatment based on a case series 2019 , 15, 223-230		2
31	Rozpoznanie i leczenie nowotworu typu angiomyolipoma (AML) 2020 , 16, 116-132		2
30	Association of breathing patterns and quality of life in patients with nasal obstruction. <i>Otolaryngologia Polska</i> , 2018 , 72, 11-15	0.7	2
29	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 723-742	3.5	2
28	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. <i>Cancers</i> , 2021 , 13,	6.6	2
27	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
26	Cerebrovascular reactivity and cerebral perfusion of rats with acute liver failure: role of L-glutamine and asymmetric dimethylarginine in L-arginine-induced response. <i>Journal of Neurochemistry</i> , 2018 , 147, 692-704	6	2
25	Efficacy of Sirolimus Treatment in PEComa-10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
24	Long-term parental satisfaction with adenotonsillectomy: a population study. <i>Sleep and Breathing</i> , 2015 , 19, 1425-9	3.1	1
23	The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats. <i>Brain Research</i> , 2015 , 1625, 218-37	3.7	1
22	The Role of Diabetes in Molecular Pathogenesis of Cancer. <i>Current Signal Transduction Therapy</i> , 2015 , 10, 10-16	0.8	1
21	Mitochondrial DNA Mutations in Tumors 2009 , 119-130		1
20	Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience. <i>Surgical Oncology</i> , 2020 , 35, 276-284	2.5	1
19	Hyperpolarized ¹³ C tracers: Technical advancements and perspectives for clinical applications. <i>Biocybernetics and Biomedical Engineering</i> , 2021 , 41, 1466-1466	5.7	1
18	Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1

17	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. <i>Cells</i> , 2021 , 10,	7.9	1
16	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	0
15	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. <i>Melanoma Research</i> , 2021 , 31, 49-57	3.3	0
14	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2021 , 1-7	2.8	0
13	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21514-e21514	2.2	0
12	What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2602-2608	3.6	0
11	Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e22537-e22537	2.2	
10	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15164-e15164	2.2	
9	Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23554-e23554	2.2	
8	Treatment obstacles for metastatic clear cell renal cell carcinoma of Fuhrman grade IV and with sarcomatoid histologies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15604-e15604	2.2	
7	Molecular factors regulating clear cell renal cancer cellsTfate: Implications for tyrosine kinase inhibitors responsiveness and toxicities.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15577-e15577	2.2	
6	Molecular events regulating clear cell renal cell cancer resistance to tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15600-e15600	2.2	
5	Gene expression profiling of primary and metastatic renal cell carcinoma tumor initiating cells.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16091-e16091	2.2	
4	The regulation of clear cell renal cancer cells proliferation and tyrosine kinase inhibitors responsiveness by tumor micro-environmental factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 488-488	2.2	
3	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21541-e21541	2.2	
2	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21521-e21521	2.2	
1	Mechanisms of Resistance to Targeted Therapies in Skin Cancers 2021 , 357-384		